The genetic polymorphism of apolipoprotein E (APOE) has been suggested to modify the effect of smoking on the development of coronary artery disease (CAD) in apparently healthy persons. The interaction of these factors in persons undergoing coronary angiography is not known.
Introduction
Smoking contributes to the development of cardiovascular disease. 1 -3 In men free of symptomatic coronary artery disease (CAD), the risk of atherosclerosis conferred by smoking has been found higher in carriers of at least one 14 allele at the apolipoprotein E (APOE) gene locus. 4 -9 A few other studies, however, did not find such an interaction between the 14 allele and smoking. 10 -13 APOE is a constituent of triglyceride-rich lipoproteins and high-density lipoproteins (HDL). There are three common alleles at the APOE locus (12, 13, and 14) which give rise to three homozygous (122, 133, 144) and three heterozygous genotypes (123, 124, 134). 14 The genetic polymorphism of APOE has been suggested to modify the rate of intestinal absorption of sterols, 15, 16 the receptor-mediated delivery of sterols to hepatocytes, 14 hepatic sterol production, 4 the expression of low-density lipoprotein (LDL) receptors, 14 and the concentration of C-reactive protein. 17 The APOE gene was among the first candidates considered relevant to the development of atherosclerosis. 18 In comparison with the wild-type allele 13, the 14 allele increases the risk of CAD, whereas the 12 allele is protective. 19 Gene-centric analysis confirmed a variant at the APOE locus to be related with CAD at genome-wide significance. 20 The impact of smoking and the APOE-genotype on vascular disease has mainly been investigated in clinically asymptomatic individuals, but not in patients scheduled for coronary angiography. Further, the question whether the APOEgenotype influences the adverse effects of tobacco use on total mortality has not been examined. We studied the role of the APOE-genotype as a modifier of the effects of smoking on death from any cause and death from cardiovascular diseases in persons who had undergone coronary angiography. 21 
Methods

Study design and participants
We studied participants of the LUdwigshafen RIsk and Cardiovascular Health (LURIC) study recruited between June 1997 and January 2000.
The study design has been described. 21 For more details, please see
Supplementary material online.
Laboratory investigations
Laboratory methods and lipoprotein analyses have been described. 21, 22, 23 The glomerular filtration rate (eGFR) was calculated from creatinine. 24 The average radius of LDL was calculated as described. 25 Oxidized LDL (oxLDL) were measured with a competitive enzyme immunoassay (Mercodia AB, Uppsala, Sweden), lipoprotein-associated phospholipase A 2 (LpPLA 2 ) with the Auto PAF-AH kit (Azwell, Inc., Osaka, Japan), and interleukin 6 (IL-6) with an enzyme immunoassay (R & D Systems, Minneapolis, MN, USA). APOE genotyping was performed as described. 26 Ambiguous genotypes (,1%) were simultaneously examined using commercial methodology. 27 
Statistics
Clinical characteristics were compared between never-smokers, ex-smokers, and current smokers with or without 14 by x 2 contingency table testing, analysis of variance (ANOVA), or logistic regression using co-variables as indicated ( Table 1) . We used the Cox proportional hazards model to examine the association between APOE-genotype ( Table 2) , smoking status (Table 3) , and the interaction of these factors with mortality from all causes ( Table 4 ) and with cardiovascular ( Table 5 ) and non-cardiovascular (Supplementary material online, Table S6 ) causes of death. The time-to-death random variable was defined as the time period between the date of birth and the date of death or the time to the last follow-up (30 April 2010) for the censored subjects. As indicated by log-minus-log diagnostic plots, the proportional hazards assumption was met. Adjustment was carried out for sex (Tables 4 and 5, Model 1) or, in addition, for the use of lipid-lowering agents (.97% statins), risk factors [body mass index, diabetes mellitus, hypertension, LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), log-transformed triglycerides, eGFR], and clinical presentation (no CAD, stable CAD, UAP, NSTEMI, or STEMI) (Model 2). When LDL-C was replaced by apolipoprotein B, there was practically no effect on the point estimates for the respective hazard ratios (HRs) (data not shown). The effect of smoking and the APOE-genotype on lipids, oxidative stress, and/or inflammation was investigated by ANOVA with covariables ( Table 6 ). The assumption that residuals are normally distributed was confirmed using plots of observed vs. predicted values. We report estimated marginal means of the dependent variables along with their 95% confidence intervals (CIs). The least significant different t-test was used for post hoc comparisons (smokers with or without 14). Tests were two-sided; P , 0.05 was considered significant. The SPSS 16.0 statistical package (SPSS, Inc.) was used.
Results
Patients characteristics
Current or past smoking was more prevalent among men than among women ( Table 1) . Never-smokers and ex-smokers were older than current smokers. Never-smokers had less CAD. Current smokers were more likely to present with STEMI than ex-smokers or never-smokers. Among ex-smokers, the proportion of persons presenting with stable CAD was higher than among never-smokers and current smokers. Current smokers had, on average, a lower body mass index than never-smokers or ex-smokers. The prevalence of diabetes mellitus was greater in ex-smokers than in never-smokers and current smokers. History of hypertension was not different across the categories. However, current smokers had lower mean systolic and diastolic blood pressures compared with never-smokers or ex-smokers, which may be related to the fact that these subjects more frequently presented with acute myocardial infarction. Among current smokers, non-carriers of 14 were significantly older than carriers of 14. No substantial differences were seen with regard to the clinical presentation, body mass index, the prevalence of diabetes mellitus, or hypertension between smokers with or without 14. Diastolic blood pressure, however, was lower in current smokers with than in those without 14.
APOE-genotype and mortality
Among the 3263 persons studied, 757 deaths (23.2%) occurred during a median follow-up time of 7.7 years. No relationship was seen between the APOE-genotype and mortality from all causes (not shown). Death certificates were available for 3239 individuals. Among these, 474 (14.5%) died due to cardiovascular diseases. When individuals were assigned to three groups according to their APOE-genotypes (E4: 124, 134, or 144; E3: 133; and E2: 122, 123), the HR for cardiovascular mortality was significantly lower in persons having either an 122 or 123 genotype ( Table 2) . Explaining the absence of any obvious association between total mortality and APOE-genotypes, non-cardiovascular mortality was increased in individuals with the genotypes 133 or 123 or 122, compared with carriers of 14 ( (14) 168 (22) 121 (21) 47 (26) Age ( (42) 732 (54) 313 (41) 251 (42) 62 (34) UAP (TnT2) 215 (19) 277 (21) 135 (18) 105 (18) 30 (17) NSTEMI (TnT+) 33 (3) 55 (4) 26 (3) 20 (3) 6 (3) STEMI (TnT+) 61 (5) 85 (6) 145 (19) 101 (17) 44 (24) Body mass index (kg/m 2 ) 27. 
Smoking and mortality
Both previous and current smoking increased the rate of all-cause and cardiovascular and non-cardiovascular deaths. After adjusting for sex ( Table 3 , Model 1) and for other risk factors ( Table 3 , Model 2), ex-smokers were at moderately, but significantly increased risk of death. Current smokers were at higher risk to die than neversmokers and ex-smokers. Among non-cardiovascular deaths, smoking increased the rates of fatal infections and cancer at approximately the same degree ( Table 3) .
Interaction of the APOE-genotype and smoking
There was no relationship between the APOE-genotype and mortality from all causes or from cardiovascular causes in both never-smokers and ex-smokers (Supplementary material online, Tables S1 and S2). We therefore stratified the cohort into four groups, namely neversmokers, ex-smokers, current smokers with, and current smokers without an 14 allele. Among current smokers, mortality was higher in those with 14 (HR 2.95, 95% CI 2.10 -4.17) than without (HR 2.07, 95% CI 1.64-2.62, Beyond mortality from all causes, we studied cardiovascular mortality in relation to the APOE-genotype and smoking. Compared with never-smokers, HRs for cardiovascular death were 1.32, 1.94, 1.74, and 2.79 in ex-smokers, current smokers, current smokers without 14, and current smokers with 14, respectively ( Table 5 , Model 1A). These HRs did not change substantially upon adjustment for major cardiovascular risk factors.
Mortality from all causes and cardiovascular mortality were also higher in smokers with 14 than in those without 14 when we considered persons without or with angiographic CAD separately. However, due to smaller numbers of events in each of the subgroups, the smoking and 14 interaction was not significant in persons without CAD, and it approached (but did not reach) .......... ............ ............ ............ ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ ....... statistical significance in the CAD group (Supplementary material online, Tables S3 and S4). We also examined whether individual causes of cardiovascular deaths were different in smokers with 14 compared with smokers without 14. This was true for death from CAD, stroke, congestive heart failure, but not for death from sudden cardiac death (Supplementary material online, Table S5 ).
We also examined whether the presence of an 14 allele amplified the risk to die from non-cardiovascular causes in current smokers. As shown in Supplementary material online, Table S6 , ex-smokers and even more so current smokers were at increased risk of mortality. However, presence or absence of an 14 allele did obviously not essentially modify the risk conferred by current smoking. Looking at individual categories among non-cardiovascular deaths revealed that the presence of an 14 allele increased the risk of both death from cancer and from infection, but this was outweighed by the fact that other non-cardiovascular deaths were less frequent in current smokers with 14 than in those without 14.
Smoking, APOE-genotype, and markers of lipid metabolism, inflammation, and oxidative stress
We used ANOVA to investigate the effects of APOE-genotypes on markers of lipid metabolism, inflammation, and oxidative stress. LDL-C, HDL-C, triglycerides, apoliproteins AI and CIII, and homocysteine were not significantly different between current smokers with 14 allele and without 14 allele (Table 6 ). However, current smokers with 14 allele had, on average, higher concentrations of apo B, oxLDL, LpPLA 2 activity, and IL-6 (P ¼ 0.057), whereas the concentration of apo E and LDL particle radius was lower.
Discussion
We completed the first study of the interaction between the APOE-genotype and smoking in relation to cardiovascular risk and mortality in persons undergoing coronary angiography. The key result is that the presence of at least one 14 allele increases the risk of mortality from any cause and mortality due to cardiovascular diseases in individuals who smoke. No such clear interaction was found between 14 and smoking as risk factors of noncardiovascular mortality. The APOE-genotype has for almost 30 years been implicated in the development of atherosclerosis. 18, 19 Mortality from all causes was not linked to any of the less frequent APOE alleles. When we subsequently analysed individual categories of death, the 12 allele was associated with lower cardiovascular mortality, while there was a (non-significant) tendency towards higher cardiovascular mortality in carriers of 14. Of interest, the opposite was true for non-cardiovascular mortality: there appeared to be a higher incidence rate of deaths in the absence of 14, which may have been driven by fatal infectious diseases rather than by fatal cancer.
Owing to a limited number of deaths due to non-cardiovascular causes, the tendency for increased death from infection was not statistically significant. We are also not able to decide whether this finding reflects an increased risk for a competing cause of death or a specific protection from infection by the 14 allele. At least, a previously established role of APOE in immune modulation would support the latter, 28 and speculations exist that the 14 may have conferred an advantage during evolution by mediating resistance to infectious diseases. 29 Previous and more so current smoking was independently associated with total mortality, cardiovascular mortality, and noncardiovascular mortality (fatal infection and death from cancer). We have particularly been interested in the hypothesis that the 14 allele modifies the adverse effects of smoking. We found a strong and more than additive interaction of current smoking and possession of at least one 14 allele; the latter attains significant prognostic importance in current smokers only, but not in neversmokers and ex-smokers. On the other hand, both previous and more so current smoking remain strong predictors of death even in the absence of 14.
The effects of smoking and the APOE-genotype have so far been studied in population-based studies such as the Northwick Park Heart Study, 5 the Framingham Offspring Study, 6, 9 and the National Heart, Lung, and Blood Institute Family Heart Study 8 showing that adverse cardiovascular effects of 14 particularly occur in current smokers. Our study confirms and extends this work to persons undergoing coronary angiography who are at an intermediate-tohigh risk of future cardiovascular events. It further demonstrates for the first time that smoking and the APOE-genotype relevantly interact in predicting total mortality. We sought to evaluate mechanisms underlying the smoking and 14 interaction. We therefore compared lipoproteins, along with markers of inflammation and oxidative stress in current smokers with or without 14. Although LDL-C did not significantly differ between the two groups, current smokers carrying 14 had significantly higher concentrations of apo B and LDL-associated apo B. The ratio of apo B to cholesterol in LDL was greater and the calculated diameter of LDL was significantly lower in smoking carriers of 14, indicating increasing proportions of small and dense LDL in carriers of 14.
30 Decreased lipoprotein lipase activity as a consequence of smoking is unlikely to contribute to this finding, because the largest difference in LDL particle diameter occurred between current smokers carrying or not carrying an 14 allele and because LDL particle diameters presented have been adjusted for triglycerides. Small and dense LDL appear to be cleared from the plasma at a decreased rate, 31 possibly by cell-surface sites different from the LDL receptor. 32, 33 As a consequence of their prolonged time of residence in the circulation and their decreased content of antioxidants (e.g. vitamin E or ubiquinone), small, dense LDL are more susceptible to oxidation. 34 -37 Evidently, as long as oxidative stress is low, this may leave LDL unaffected. However, once small, dense LDL are exposed to pro-oxidants in smokers, appreciable amounts of oxLDL (and foam cells) may be generated. It is in line with these considerations that we found higher concentrations of oxLDL and higher activities of LpPLA 2 , a marker of unstable plaques, in current smokers with 14 compared with those without 14. A report by Talmud et al. 9 points in the same direction. They found elevated oxLDL in the plasma of smokers with 14.
It is yet an open question whether this is due to a direct effect of the APOE-genotype on the antioxidant capacity of the plasma. At least theoretically, such a possibility exists. Apo E2 contains two and apo E3 contains one free thiol groups per molecule, although no free thiol group is available in apo E4. Apo E4 may therefore have completely lost any anti-oxidative capacity. 38, 39 However, we believe that this is hardly relevant in vivo:
Only one out of five LDL particles contains one molecule of APOE 40 ; APOE-containing particles are rapidly cleared, 41 and apo E4 preferentially associates with HDL, but less with LDL. Thus, predominance of small, dense LDL caused by 14 may largely explain the observed 14 × smoking interaction.
Are there clinical consequences of the current results? Advice to quit smoking should be given to any individual, regardless of the APOE-genotype. This in particular applies to persons at elevated risk of cardiovascular events as they participated in the LURIC study. Good reasons might exist, however, to obtain APOE-genotypes in persons who fail to quit smoking, because their risk is still amplified considerably. First, it has been demonstrated that awareness of individual genetic susceptibility factors could potentially enhance interventions aiming at smoking cessation. 42 Second, because the effects of 14 may be attributable to the accumulation of small dense LDL, lipid-lowering treatment might be further intensified following detection of 14 in smokers. This is the first investigation to demonstrate a significant interaction between the 14 allele at the APOE locus and current smoking as risk factors predicting cardiovascular and all-cause mortality. Future research will have to address whether or not the assessment of the APOE-genotype possibly along with other susceptibility genes will support efforts to prevent CAD by behavioural changes.
Supplementary material
Supplementary material is available at European Heart Journal online.
